Showing results (121-130 of 162) with videos related to

Sort By:
Pageof 17
Haematologica|May 30, 2013
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohortsSabina Chiaretti, Antonella Vitale, Gianni Cazzaniga, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Blood Advances|September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA studyStephen Opat, Alessandra Tedeschi, Bei Hu, et al.
British Journal of Haematology|March 9, 2026
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre studyNicolò Danesin, Francesco Autore, Anna Maria Frustaci, et al.
Blood|July 20, 2002
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaAgostino Tafuri, Chiara Gregorj, Maria T Petrucci, et al.
American Journal of Hematology|March 10, 2025
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom MacroglobulinemiaJonas Paludo, Jithma P Abeykoon, Nirosha D Perera, et al.
British Journal of Haematology|December 15, 2015
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström MacroglobulinaemiaLian Xu, Zachary R Hunter, Nicholas Tsakmaklis, et al.
American Journal of Hematology|August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studiesTadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
Immunogenetics|November 13, 2014
Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemiaAliki Xochelli, Andreas Agathangelidis, Ioannis Kavakiotis, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Pageof 17